Last reviewed · How we verify

LCZ 696 — Competitive Intelligence Brief

LCZ 696 (LCZ 696) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin receptor-neprilysin inhibitor (ARNI). Area: Cardiovascular.

marketed Angiotensin receptor-neprilysin inhibitor (ARNI) Angiotensin II type 1 receptor (AT1R); Neprilysin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

LCZ 696 (LCZ 696) — National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. LCZ696 is a dual angiotensin receptor-neprilysin inhibitor (ARNI) that blocks angiotensin II signaling while inhibiting neprilysin to increase natriuretic peptides.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LCZ 696 TARGET LCZ 696 National Medical Research Center for Cardiology, Ministry of Health of Russian Federation marketed Angiotensin receptor-neprilysin inhibitor (ARNI) Angiotensin II type 1 receptor (AT1R); Neprilysin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin receptor-neprilysin inhibitor (ARNI) class)

  1. National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LCZ 696 — Competitive Intelligence Brief. https://druglandscape.com/ci/lcz-696. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: